bmx-010
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2014 (NCT02457858)
Timeline
Indications
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297709 ↗
Also known as
- bmx-010
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05491447 | Phase 2 | Nov 8, 2022 | BioMimetix Pharmaceutical, Inc., Innovaderm |
| NCT03752242 | Phase 2 | Jan 3, 2019 | BioMimetix Pharmaceutical, Inc. |
| NCT03756389 | Phase 2 | Jan 3, 2018 | BioMimetix Pharmaceutical, Inc. |
| NCT03381625 | Phase 2 | Jan 2, 2018 | BioMimetix Pharmaceutical, Inc. |
| NCT02457858 | Phase 1 | Aug 1, 2014 | BioMimetix Pharmaceutical, Inc., University of Alberta |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioMimetix Pharmaceutical, Inc. | For profit | 5 | 4 | 2 | 2014 |
| Innovaderm | For profit | 1 | 0 | 1 | 2022 |
| University of Alberta | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1